Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
admission, akin, Alexion, appellate, argued, ATA, Bacteria, behavior, broker, caption, Carolina, Citigroup, COMP, complement, constraint, construction, corridor, CSR, currency, default, depiction, description, Diego, discreet, dismissal, Distinguishing, ECG, electrocardiography, Eli, epithelial, expedient, fit, fulfill, fulfilled, GDPR, grantor, growing, Hayden, heading, headquartered, HHS, Hong, HVs, immaterial, incorrect, inseverable, installation, instrument, Intellia, interdependence, interdependent, interrelation, intestinal, Ireland, Janssen, judge, Kong, Lexington, licensee, lifelong, Lilly, magnitude, membership, mmol, monopolization, motion, move, neural, neurodegeneration, nonvested, Northern, officially, OIG, Oligo, ordinary, Park, permission, phantom, plain, possessing, PPF, predominant, prejudice, principle, proper, recalculated, recast, reclassification, regular, replicate, resale, restraining, retention, reward, Roth, salary, Sherman, sought, staffing, steering, Sublandlord, sublease, sugar, susceptible, Thailand, tradeable, transient, trust, turnover, unconditional, unconsolidated, unconstitutional, underwritten, Unlimited, unsatisfied, USD, vanilla, vital, whichever, worth, wrongdoing
Removed:
abnormally, academic, accrual, aforementioned, aimed, Amgen, answer, antibody, antitrypsin, APOLLO, ATTR, bankruptcy, baseline, Benitec, Brian, Bruce, buyer, carcinoma, COH, confirming, conjugate, conventional, Copenhagen, copied, copy, correct, counterparty, CPD, cytoplasm, David, demonstrating, Dentzer, denying, differentiated, disclosing, double, DsiRNA, duly, ear, educational, eliminating, employ, EnCore, endure, enjoining, Europe, exhibit, eye, factor, familial, formulated, Genzyme, guarantor, Hakko, Halak, heart, hemophilia, hepatic, hereof, herewith, Hoffman, IDT, implicated, inAssociation, includingin, indemnification, Independence, inflammatory, inin, Institute, Integrated, IP, irrevocably, Jack, KHK, King, Kirin, Kolchinsky, Kyowa, Langer, Madden, measurable, mediated, mimic, miRagen, multicenter, NCI, NE, negligible, nonclinical, nonrefundable, observational, oncology, optimize, orin, orRule, output, OxThera, page, painful, particle, partnered, Peacock, Peter, pharmacokinetic, preferential, processing, Quark, ratify, recruiting, reliably, rendered, resubstitution, Room, Roughly, RXi, screening, seller, Separation, serving, signature, situated, Spain, Specimen, stead, Stephen, structured, subcontractor, sublicensee, subsisting, substitute, substrate, successor, Takeda, thereunto, therewith, thing, tolerated, true, twelve, uncured, undercut, undersigned, upstream, vigorously, virtue, Washington, wrong
Filing tables
Filing exhibits
Related press release
Associated DRNA transcripts
DRNA similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-202687, 333-214082, 333-223778, and 333-224989 on Form S-3 and in Registration Statement Nos. 333-193795, 333-210071, and 333-223648 on Form S-8 of our report dated March 13, 2019, relating to the consolidated financial statements of Dicerna Pharmaceuticals, Inc. and its subsidiaries appearing in this Annual Report on Form 10-K of Dicerna Pharmaceuticals, Inc. for the year ended December 31, 2018.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 13, 2019